June 16, 2024
Antisense Oligonucleotides Market

Antisense Oligonucleotides Market Set to Register High Growth Due to Increasing Investments in R&D Activities

The antisense oligonucleotides market comprises products that help regulate gene expression through modulation of DNA or RNA. Antisense oligonucleotides are short, synthetic strands of nucleotides used to alter the activity of specific genes. They typically bind to mRNA or pre-mRNA molecules through Watson-Crick base pairing, inhibiting mRNA translation or inducing mRNA degradation to prevent the expression of disease-causing proteins. The growing prevalence of various diseases including cancer, cardiovascular disorders, and neurological conditions has accelerated the demand for antisense oligonucleotides as they allow targeted delivery of treatment with greater specificity and fewer side effects compared to conventional small-molecule drugs.

The Global antisense oligonucleotides market is estimated to be valued at US$ 3356.36 Mn in 2024 and is expected to exhibit a CAGR of 7.1% over the forecast period from 2024 to 2031.

Key Takeaways

Key players operating in the antisense oligonucleotides market are SICK AG, Hitachi Ltd., Honeywell International Inc., Hyundai Elevator Co. Ltd., Nidec MCE, Toshiba Elevators and Building Systems, Thames Valley Controls, and Mitsubishi Electric. These players are focusing on R&D activities to develop innovative antisense oligonucleotides for the treatment of various diseases. For instance, Ionis Pharmaceuticals has advanced multiple antisense oligonucleotide drugs in clinical trials for neurological and cardiovascular diseases.

The increasing prevalence of chronic diseases worldwide has opened lucrative opportunities for antisense oligonucleotides manufacturers. In addition, growing awareness regarding precision medicine and targeted therapies is expected to further drive the demand. Moreover, strategic collaborations between pharmaceutical companies and research organizations are boosting ongoing clinical research for new antisense oligonucleotide drugs.

The global expansion of key players through partnerships, joint ventures, and new facility openings in regions such as Asia Pacific and Latin America will further augment the Antisense Oligonucleotides Market Growth during the forecast period. For example, in December 2021, Sarepta Therapeutics opened a new R&D facility in China to accelerate drug development programs for Duchenne muscular dystrophy and other genetic diseases.

Market drivers

The rising R&D investments by both public and private players is a key factor anticipated to boost the antisense oligonucleotides market growth. Government agencies and pharmaceutical companies are increasingly funding clinical research activities for promising antisense oligonucleotides drugs. Moreover, growing healthcare expenditure across major countries and availability of favorable reimbursement policies are also projected to propel the market demand for antisense oligonucleotides over the forthcoming years.

PEST Analysis

Political: Regulations laid down by governments related to clinical trials and product approvals can impact the growth of the antisense oligonucleotides market. However, supportive policies can promote R&D in this area.

Economic: High R&D costs associated with new drug development and uncertainty around product success pose economic challenges. However, growing healthcare budgets worldwide provide economic opportunities.

Social: Growing awareness about certain diseases and their treatment options is prompting social demand for advanced therapies. Rising social acceptance of genetic interventions is a key social driver.

Technological: Advances in oligonucleotide chemistry, delivery methods and manufacturing technologies are improving efficacy, safety and production capabilities. Further innovations are expected to expand applications and market potential.

The North American region currently holds the largest share of the antisense oligonucleotides market in terms of value. Major factors contributing to this include the large patient pool suffering from cancer and other target diseases, increasing research activities, and presence of prominent market players. The Asia Pacific region is projected to witness the fastest growth during the forecast period owing to rising healthcare expenditures, growing incidences of genetic disorders, and improving research infrastructure.

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it